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Objective: Surgery for allergic fungal sinusitis in the absence of continued medical management is associated with an
unacceptably high rate of recurrence. There is no agreement on the proper postoperative medical treatment
Method: Eighteen patients with allergic fungal sinusitis were treated by surgical treatment and divided into 2 groups.
Nine patients received postoperative immunotherapy and the remaining 9 patients did not receive immunotherapy. Both
groups received otherwise the same postoperative care and were compared regarding the symptom score, mucosal staging,
and number of oral corticosteroid courses, outpatient procedures and revision surgeries.
Results: There was statistically significant difference between the symptom score of nasal obstruction in patients who
received immunotherapy (0.67 ± 0.5) compared to patients who did not receive immunotherapy (1.44 ± 0.53) P˂ 0.05. The
endoscopic staging for mucosa was less in patients who received immunotherapy (0.78 ± 0.67) versus (1.78 ± 0.67) in the
other group P=0.05. The number of oral corticosteroid courses or outpatient procedures was considerably less in patients
who received immunotherapy (1 ± 0.71) versus (3.2 ± 1.2) in the other group P˂ 0.005. Revision surgery was performed in 1
patient (11%) in the group who received immunotherapy and in 3 patients (33%) in the other group
Conclusion: Sublingual immunotherapy is safe and effective in the postoperative treatment of allergic fungal sinusitis.
Keywords: Allergic fungal sinusitis, sublingual immunotherapy.

INTRODUCTION
Fungal sinusitis is classified into four categories: acute
invasive fungal sinusitis, chronic invasive fungal sinusitis,
mycetoma
(fungal
ball)
and
allergic
fungal
sinusitis.(AFS)(1)
According to Bent and Kuhn, the major criteria for
diagnosis of AFS are: type I hypersensitivity, nasal
polyposis, characteristic CT findings, the presence of
eosinophilic mucin without invasion and a positive fungal
stain of sinus contents removed at the time of surgery. The
minor criteria that support diagnosis include: history of
asthma, unilateral predominance of the disease,
radiographic evidence of bone erosion, fungal cultures,
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presence of Charcot-Leyden crystals in surgical specimens
and eosinophilia.(2)
Examination of the allergic fungal mucin itself and not the
surrounding mucosa is the most reliable indicator of the
disease. Grossly the mucin is thick, highly viscous,
variably coloured and described as being similar to peanut
butter or axle grease. Microscopically, the mucin shows
sheets of eosinophils, frequently with the presence of
eosinophilic breakdown products or Charcot-Leyden
crystals.(3)
Aspergillus species are believed to be the predominant
cause of allergic fungal sinusitis.(4)
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It is accepted that complete removal of allergic mucin and
maintenance of adequate paranasal sinus drainage is the
initial step of therapy. Unfortunately, surgery in the
absence of continued medical management is associated
with an unacceptably high rate of recurrence.(5)
There have been anecdotal reports of the use of postoperative Itraconazole. Long-term, repeated courses of
oral corticosteroids reduce symptomatic recurrence.
However, such treatment must be avoided in patients
with diabetes, blood dyscrasias, immunodeficiency,
glaucoma, osteoporosis and hepatitis. Topical steroids also
help reduce symptomatic recurrence.(4)
Immunotherapy was introduced as a treatment in the
long-term control of AFS. It is the only therapeutic option
that modifies the basic allergic mechanism by inducing
desensitization and an anergy state for the allergen.(6)
The rationale for immunotherapy is that AFS is at least
partially a result of allergen-specific IgE-mediated
inflammation. Although the relative importance of type 1
hypersensitivity in AFS continues to be debated, by
definition AFS patients have fungal allergy.(7)
Immunotherapy increases allergen tolerance with
reorientation of allergen-specific CD4+ T-cell responses
from a T helper 2 (Th2) to Th1 and regulatory T-cell
profiles. Allergen exposure modifies serum levels of
allergen-specific IgE and IgG, although there is
considerable debate as to whether these parameters are
related to clinical efficacy.(8)
The work of Mabry and colleagues suggested that
injection immunotherapy to fungal allergens may be
effective in the treatment of symptoms of allergic fungal
sinusitis and decreases the rate of allergic fungal sinusitis
exacerbations postoperatively with less revision
surgeries.(9,10) However, injection immunotherapy is
associated with rare but real risks of anaphylaxis and
death. Injection immunotherapy must be administered in
an appropriately supervised physician’s office on a
repeated basis, from once a week to once a month over
several years.
Sublingual immunotherapy has a good safety profile
that appears to be better than subcutaneous
immunotherapy, and has been taken at home in Europe
for 20 years.(11) In contrast to subcutaneous injection
immunotherapy, sublingual immunotherapy appears to
elicit mucosal IgA responses, which may contribute
significantly to tolerance induction.(9)
In this study the effect of sublingual immunotherapy in
treatment of allergic fungal sinusitis following surgery
was assessed.
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PATIENTS AND METHODS
Eighteen patients who met the criteria of diagnosis of
allergic fungal sinusitis were included in this study. These
patients presented in Fakeeh Hospital and United Doctors
Hospital, Jeddah, KSA, between January 2007 and
December 2009.
The criteria for diagnosis were nasal polyps, allergic
mucin, CT scan findings in the form of increased
attenuation of the sinus contents (figure 1), positive skin
prick test for fungal allergen and positive fungal stain by
silver stain. The skin prick test was positive for
Aspergillus species in all patients with or without other
allergens. The skin prick test was considered positive
when the wheal size for Aspergillus mix was >3mm, the
negative control was ˂ 3mm and the positive control was
>3mm. Fourteen out of the 18 patients had positive fungal
culture as well. All the patients were subjected to
endoscopic sinus surgery with excision of the polyps and
fungal mucin from the affected sinuses. All the patients
were treated by postoperative local corticosteroids in the
form of Mometazone Furoate 2 puffs once daily all
through the postoperative follow up period. Nine of the
patients started sublingual specific immunotherapy for
Aspergillus species (Stallergens, Antony, Paris, France)
one month postoperatively (Group 1). The other 9 patients
did not receive immunotherapy for different reasons
(Group 2). The first group consisted of 6 males and 3
females with the age ranging from 15 to 33 years old while
the second group consisted of 5 males and 4 females with
the age ranging from 14 to 31 years old. Both groups were
similar demographically with regard to patient age, sex,
and length of follow-up. The duration of immunotherapy
was 2 years starting one month after surgery. The dose
starts by 1 drop of the 10 IR/ml concentration sublingual
in day one. The dose gradually increases to 2, 4, 6 and 8
drops in the following days. Once this dose is reached, the
other vial with 100 IR/ml concentration is started and
again the dose increases from 1 drop to 2, 4, 6 and 8 drops
in the following days. Once this dose is reached, the
immunotherapy is taken every other day till the end of the
course. The drops should be taken in the morning and
kept under the tongue for 2 minutes then swallowed.
Follow up of patients was scheduled weekly for one
month postoperatively for suction of crusts and debris
then every month for two years.
When the patient had severe symptoms with recurrent
polyps and fungal debris, short course of oral
corticosteroid (prednisolone) 30 mg/day for 5 days was
used. When there is contraindication to systemic
corticosteroids, outpatient endoscopic procedures for
excision of polyps and suction of fungal mucin were
performed. Revision surgery was indicated if these
measures did not improve the condition or the outpatient
procedure was not tolerated. Both groups were compared
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regarding nasal obstruction symptom, endoscopic staging
of nasal and sinus mucosa according to Kupferberg,(12)
number of systemic corticosteroid therapy courses or
outpatient procedures and number of revision surgery
after 2 years of follow up.
Symptom score was graded from 0 to 3 with 3 being
worst. In Kupferberg endoscopic staging system, stage 0
means no evidence of disease, stage 1 oedematous
mucosa/allergic mucin, stage 2 polypoid mucosa/allergic
mucin and stage 3 polyps and fungal debris.(12) All the
patients had stage 3 nasal and sinus mucosa and symptom
score of 3 before treatment.
Statistical analysis was performed using t-student test
considering α = 0.05. The continuous variables were
expressed as mean ± standard deviation.

Revision surgery was performed in 1 patient (11%) in
group 1 and in 3 patients (33%) in group 2.
Table 1. The age, gender, symptom score, staging of
mucosa, and the number of oral corticosteroid courses
or outpatient procedures after 2 years of follow up.
OCC (oral corticosteroid course), OPP (outpatient
procedures).
Group 1

Group 2

15-33

14-31

6/3

5/4

Symptom score

0.67±0.5

1.44±0.53

Staging of mucosa

0.78±0.67

1.78±0.67

1±0.71

3.2±1.2

Age
Male/female

Number of OCC or OPP

Fig 1. CT scan of a patient with allergic fungal
sinusitis showing the characteristic increased
attenuation of sinus contents.

Fig 2. Symptom score in group 1 with immunotherapy
and 2 without immunotherapy after 2 years of follow up.

RESULTS
Apart from localized mouth itching in 2 patients no
complications of sublingual immunotherapy were
recorded in this study. This itching was only transient in
the beginning of immunotherapy and was treated by
antihistamine tablets.
After 2 years of follow up, the symptom score of nasal
obstruction in group1 was 0.67 ± 0.5 and in group 2 was
1.44 ± 0.53 P˂ 0.05. (Fig. 2).
After 2 years of follow up the endoscopic staging for
mucosa in group 1 was 0.78 ± 0.67 and in group 2 was
1.78 ± 0.67 P˂ 0.05. (Fig. 3).
The number of oral corticosteroid courses or outpatient
procedures after 2 years of follow up in group 1 was 1 ±
0.71 and in group 2 was 3.2 ± 1.2 P<0.005. (Fig. 4) Table 1.
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Fig 3. Staging of nasal mucosa in both group 1 with
immunotherapy and 2 without immunotherapy after 2
years of follow up.
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group had a statistically significant decline in disease
activity compared with control subjects as measured by
AFS endoscopic mucosal staging. Mean scores of chronic
sinusitis survey were significantly higher in the
immunotherapy group than the control group. A
dramatically reduced corticosteroid requirement was
noted in the immunotherapy group.(14)

Fig 4. Number of oral corticosteroid courses and
outpatient procedures in both groups after
2 years of follow up.

DISCUSSION
The reasons for the high rate of recurrence in patients with
AFS are not clearly understood. Inadequate surgical
removal of fungal disease, re-exposure to fungi, persistent
microscopic fungal colonization or factors leading to
mucosal swelling and inflammation are all potential
causes for recurrent AFS.(5)
Treatment with systemic steroids was used in different
studies to maintain control of polypoid inflammation. It
was observed that the time to revision surgery was
prolonged in the group receiving steroids. However,
because of the potential side effects of systemic
corticosteroids, alternative forms of therapy are needed.(13)
Systemic steroids are best confined to the perioperative
period and for use in short bursts to suppress recurrent
polyps and acute exacerbations of disease. The antiinflammatory effect of specific allergen immunotherapy
has the potential to decrease reliance on systemic steroids
in the treatment of AFS and may reduce the need for
revision surgery.(7)
Mabry et al in 1997 reported the use of subcutaneous
immunotherapy directed against specific fungal antigens
after skin testing and preceded by definitive surgery in 9
patients. There was no control group but no side effects
were reported and less allergic mucin and crusts were
noted following treatment.(9)
Mabry et al in 1998 reported 23 patients with less
recurrence
of
AFS
following
subcutaneous
immunotherapy.(10)
In a study by Folker et al (1998) 11 patients with AFS who
received subcutaneous immunotherapy were compared
with a control group of 11 patients. The immunotherapy

PAJR, Vol. 2, No. 1, March, 2012

In a study by Bassichis et al (2001), 8 (33.3%) of the 24
patients without immunotherapy required revision
surgery for recurrence of polyps or allergic mucin and
only 4 (11.1%) of the 36 patients receiving immunotherapy
required repeat surgery. The total number of visits
requiring interventions averaged 4.79 visits per patient
who did not receive immunotherapy versus 3.17 visits per
patient for those who were receiving immunotherapy.(5)
In the current study there was statistically significant
difference between the symptom score of nasal
obstruction in patients who received immunotherapy
compared
to
patients
who
did
not
receive
immunotherapy. The endoscopic staging for mucosa was
markedly less in patients who received immunotherapy.
The number of oral corticosteroid courses or outpatient
procedures was considerably less in patients who received
immunotherapy. Revision surgery was performed in 1
patient in the group who received immunotherapy and in
3 patients in the other group. The sublingual
immunotherapy was found to be safe, convenient to
patients and was taken at home with no need to be
received in a health facility.

CONCLUSION
Sublingual immunotherapy is safe and effective in the
postoperative treatment of allergic fungal sinusitis.
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